2023 New Specialty Drug and Biosimilar Approvals

Program Description

The United States Food and Drug Administration approves various new specialty medications and biosimilars each year. Pharmacists play a crucial role on the health care team through their expertise on these newly approved specialty medications and biosimilars and can provide patients with the best care possible through their knowledge of how to effectively use these new medications and mitigate potential adverse effects. Pharmacy technicians also play an important role in ensuring patients are equipped with the information they need to ensure the correct dosage and safe use of these agents. This activity will include a list of novel specialty medications and biosimilars approved in 2023 with information about each of their indications. In addition, the activity will further explore select medications to highlight important characteristics, such as mechanism of action, dosing, administration, safety and efficacy, and considerations for access. Pharmacists and pharmacy technicians must stay abreast of the nuances in indications and potential role of new specialty medications and biosimilars so they can continue to optimize care for their patients.

Target audience: Health-system pharmacists, retail pharmacists and specialty pharmacists

Type of activity: Knowledge
Release date: March 11, 2024
Expiration date: March 11, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational
Fee: Free

Pharmacist Educational Objectives

At the completion of this activity, participants will be able to:

• Recognize the approved indications of select new specialty medications and biosimilars approved by the US Food and Drug Administration in 2023
• Review key characteristics of the reviewed medications including dosing, administration, and safety

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity numbers 0290-0000-24-058-H01-P and 0290-0000-24-058-H01-T. The activity is available for CE credit through March 11, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Libbi Green, PharmD, has no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms